4/22/2014 8:16:45 AM
In a second dramatic reversal for a promising treatment for a terrible disease, Sarepta Therapeutics SRPT +2.24% announced that it will file an application with the Food and Drug Administration for its drug eteplirsen, to treat Duchenne muscular dystrophy that is caused by a specific mutation, by the end of 2014. The news should please both investors and patient advocates who have campaigned for the drug’s approval.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by